BioGaia's prelim Q4 sales rise 21%, margins expand 

About this update from Biogaia Ab Class B

Overview Swedish probiotic firm's preliminary Q4 sales rise 21%, beating analyst expectations Preliminary Q4 operating profit rises 17% with a 27% margin Results are preliminary and will be finalized in February 2026 Outlook BioGaia did not provide specific guidance for future quarters or full year Result Drivers INDIVIDUAL ORDERS - Sales were positively affected by quarterly variations for individual orders amounting to approximately SEK 35 million Key Details Metric Beat/Miss Actual Consensus Estimate Q4 Sales Beat SEK 441 mln SEK 389.75 mln (2 Analysts) Q4 EBIT Beat SEK 121 mln SEK 96.35 mln (2 Analysts) Q4 EBIT Margin 27.00% Analyst Coverage The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell" The average consensus recommendation for the pharmaceuticals peer group is "buy." Wall Street's median 12-month price target for Biogaia AB is SEK135.00, about 23.4% above its February 2 closing price of SEK109.40 The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 26 three months ago Press Release: For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

View stock analysis, news, and events for Biogaia Ab Class B